Q-omics provides the consensus-scored RAB3A profile across patient tissues and cancer cell-line models. RAB3A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, RAB3A is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, RAB3A protein abundance shows 24,001 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCEC, KIRC, and GBM as cancer lineages where RAB3A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAB3A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAB3A survival associations across molecular data types. RAB3A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAB3A RNA expression–survival associations across cancer types. High RAB3A expression shows unfavorable associations in UCEC, LAML and THYM, but favorable associations in KIRP, KIRC and LUSC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for RAB3A RNA expression.
This table summarizes RAB3A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RAB3A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAB3A shows lower tumor expression in KIRC and READ and higher tumor expression in LIHC, KICH, BRCA and LUAD. The KIRC box plot shows higher RAB3A RNA expression in normal versus tumor tissue (log2 FC = −0.940, t-test p < 0.001).
This table shows molecular features associated with RAB3A in patient tissues and cancer cell lines. In patient samples, RAB3A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RAB3A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and SKIN.
